Clinical trials: Depression, Unipolar
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111565
- Testing
- Escitalopram, Aripiprazole
- Where
- 53 sites in United States, Canada and 9 more
- Volunteers
- 137 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Contact: Developing New Clinical Management Strategies
The goal of this study is to develop new methods of administering antidepressant medications that will result in improved drug/placebo separation in randomized controlled trials (RCTs) for Major Depressive Disorder (MDD) and…
- Trial name
- NCT03812588
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Alcohol Use Disorder
Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder
The investigators will compare 3 treatment groups (ketamine plus naltrexone vs. ketamine alone vs. placebo) for treating major depressive disorder (MDD) and alcohol use disorder (AUD) in an 8-week randomized, double-blind…
- Trial name
- NCT02461927
- Testing
- Ketamine + Naltrexone
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- VA Office of Research and Development
Bipolar Disorder, Major Depressive Disorder
Study Using Pregnenolone to Treat Bipolar Depression
Primary purpose of this study is to determine if pregnenolone supplementation is associated with greater improvement in depressive symptoms of patients with bipolar disorder.
- Trial name
- NCT01409096
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
This study examines the difference in the effectiveness of two natural compounds, eicosapentanoic (EPA) and docosahexanoic (DHA)omega-3 fatty acids, in treating major depressive disorder.
- Trial name
- NCT00361374
- Testing
- eicosapentaenoic acid, docosahexaenoic acid
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- Massachusetts General Hospital
Depression, Depressive Disorder, Major
A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise
This pilot study aims to test a model that predicts that enhanced neurotransmitter gamma-aminobutyric acid (GABA) function in reward and affect-regulation central nervous system (CNS) circuits mediates the antidepressant effects…
- Conditions
- Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression
- Trial name
- MEDEX (NCT02407704)
- Testing
- Venlafaxine XR, Aerobic Exercise, Lorazepam
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Kirk Erickson, PhD
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder, MDD
Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder
The primary purpose of this study is to test the safety and feasibility of virtual reality (VR) technology in the use of behavioral activation (BA) as a treatment for major depressive disorder (MDD).
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT04268316
- Testing
- Virtual Reality Behavioral Activation, Behavioral Activation in real-life
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Major Depressive Disorder
The Effects of Videogames on Depression Symptoms and Brain Dynamics
The purpose of the study is to evaluate the effects of a game-based digital-therapeutics (DTx) medical software device on the symptoms of depression in adults with confirmed major depressive disorder.
- Trial name
- NCT05426265
- Testing
- MEL-T01, MEL-S01
- Where
- 6 sites in Finland
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Aalto University
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
This study will evaluate the efficacy, safety, and tolerability of two doses of rapastinel, 225 milligrams (mg) and 450 mg, compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder…
- Trial name
- NCT02943564
- Testing
- Rapastinel
- Where
- 66 sites in United States
- Volunteers
- 658 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)
This randomized, double-blind, placebo-controlled, multicenter, 8-week, clinical trial is designed to assess the efficacy and safety of vilazodone and to evaluate genetic biomarkers of treatment response associated with…
- Trial name
- NCT00683592
- Testing
- vilazodone
- Where
- 9 sites in United States
- Volunteers
- 481 people
- Sponsor
- Forest Laboratories
Mood Disorders, Bipolar Disorder
Technology Enhanced Family Treatment
The investigators propose to enhance the scalability of family-focused therapy (FFT), a 12-session evidence-based therapy for youth at high risk for mood disorders, through augmentation with a novel mobile phone application…
- Conditions
- Mood Disorders, Bipolar Disorder, Major Depression
- Trial name
- NCT03913013
- Testing
- Family-Focused Treatment with MCC App
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes
This study will evaluate the efficacy of Vortioxetine in the prevention of relapse of major depressive episodes in patients who responded to open-label treatment with Vortioxetine.
- Trial name
- NCT00596817
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 639 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
A Study of the Effect of LY2216684 on Lorazepam
The purpose of this study is to determine how much lorazepam gets into the blood and how long it takes the body to get rid of it when given together with LY2216684.
- Trial name
- NCT01275144
- Testing
- LY2216684, Lorazepam
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
- Trial name
- NCT03668600
- Testing
- Rapastinel
- Where
- 74 sites in United States
- Volunteers
- 230 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depressive Disorder, Major
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- orvepitant MDD (NCT00880399)
- Testing
- orvepitant
- Where
- 20 sites in United States, Canada
- Volunteers
- 328 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years).
- Trial name
- NCT02709655
- Testing
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day
- Where
- 98 sites in United States, Bulgaria and 17 more
- Volunteers
- 683 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
Study Comparing Discontinuation Symptoms in subjects with Major Depressive Disorder treated for 24 Weeks with Open-label 50 mg Desvenlafaxine Succinate Sustained-Release Formulation (DVS SR)
- Trial name
- NCT01056289
- Testing
- Desvenlafaxine Succinate Sustained-Release Formulation 50 mg, Desvenlafaxine Succinate Sustained-Release Formulation 25 mg
- Volunteers
- 480 people
- Sponsor
- Pfizer
Major Depressive Disorder
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term…
- Trial name
- NCT03538691
- Testing
- Brexpiprazole, Antidepressant therapy
- Where
- United States
- Volunteers
- 1,149 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.